Key result
Exogenous PGI2 significantly decreased thrombin-induced platelet adherence to ASA-treated cell monolayers, though subendothelial components still exhibited ≥25% adherence despite high PGI2.
Why the study?
Does exogenous prostacyclin (PGI2) prevent thrombin-induced platelet adherence to cultured vascular cells and subendothelial components?
Population
In vitro cell cultures including human umbilical vein or arterial endothelium, venous or arterial smooth…
Comparison
Exogenous prostacyclin added to 1 mM… vs Cell monolayers without exogenous PGI2 or…
Design
Preclinical
Authors
Loading...
PGI2 attenuates thrombin-induced platelet adherence to ASA-treated monolayers but not subendothelium; leaves open whether adjunctive strategies are required in vivo.
Does exogenous prostacyclin (PGI2) prevent thrombin-induced platelet adherence to cultured vascular cells and subendothelial components?
This preclinical study demonstrates that while prostacyclin reduces platelet adherence to endothelial cells, it is insufficient on its own to completely prevent thrombin-induced platelet adherence to subendothelial components like smooth muscle and fibroblasts.
Fry et al. (1980) studied Platelet adherence. Prostacyclin (PGI2) vs. Absence of PGI2 / ASA-treated cells was evaluated on Platelet adherence. Exogenous PGI2 significantly decreased thrombin-induced platelet adherence to ASA-treated cell monolayers, though subendothelial components still exhibited ≥25% adherence despite high PGI2.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: